Search - tctmd.com

Displaying 1 - 20 of 22

Sort: Relevancy | Date

$Coronary Sinus Reducer ‘Promising’ for Refractory Angina: Meta-analysis$

News Daily News

Coronary Sinus Reducer ‘Promising’ for Refractory Angina: Meta-analysis

Todd Neale

August 13, 2025

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for January 2025

Shelley Wood

January 31, 2025

News Conference News TCT 2024

Colchicine Surprise: No Help Post-MI, Large CLEAR SYNERGY Trial Shows

Michael O'Riordan

October 29, 2024

News Conference News ESC 2024

ESC’s 2024 CCS Guidelines Embrace New Data, Smooth Old Tensions

Michael O'Riordan

September 17, 2024

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for May 2024

Shelley Wood

May 31, 2024

$Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC$

News Conference News ACC 2024

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Michael O'Riordan

April 08, 2024

News Conference News AHA 2023

Placebo-Controlled ORBITA-2 Shows PCI Eases Symptoms in Stable Angina

Michael O'Riordan

November 11, 2023

News Conference News ESC 2023

STEP-HFpEF: Semaglutide Cuts Weight and Symptoms, Boosts Function

Shelley Wood

August 25, 2023

News Conference News EuroPCR 2023

Meta-analysis Finds No Excess Mortality Risk With Coronary Revascularization

Michael O'Riordan

May 19, 2023

News Daily News

CV Risk Disparities by Race/Ethnicity Persist in Childhood Cancer Survivors

Yael L. Maxwell

April 13, 2023

News Conference News ACC 2023

AIMI-HF Misses Mark With Advanced Imaging in Ischemic HFrEF Workup

L.A. McKeown

March 09, 2023

News Daily News

Most Patient-Reported Outcome Measures in CVD Fall Short

L.A. McKeown

September 23, 2022

News Conference News ACC 2022

No Difference in 1-Year QoL Between FFR-Guided PCI and CABG: FAME-3

Michael O'Riordan

April 13, 2022

News Daily News

USPSTF at Last Takes Tougher Stance on Aspirin in Primary Prevention

Shelley Wood

October 15, 2021

News Conference News EuroPCR 2020

No Survival Benefit With Revascularization in Stable CAD, Meta-analysis Confirms

Michael O'Riordan

June 26, 2020

News Conference News ESC 2019

CLARIFY at 5 Years: Angina Predictive of MI/CV Death Only in Prior MI Patients

Shelley Wood

September 03, 2019

News Conference News ESC 2019

New ‘Chronic Coronary Syndrome’ Guidelines Stress There’s Nothing Stable About CAD

Shelley Wood

August 31, 2019

News Daily News

Dreams Dashed: Intravascular Therapy for MS Flops in Sham-Controlled Trial

L.A. McKeown

December 05, 2017

News Conference News TCT 2017

ORBITA: PCI Offers No Symptom Improvement Over Sham Procedure

Michael O'Riordan

November 02, 2017

News Daily News

Pharmacist Management of High Cholesterol Gets More Patients to Goal, Lowers LDL Levels: RxACT

Michael O'Riordan

September 29, 2016

Advertisement

Coronary Sinus Reducer ‘Promising’ for Refractory Angina: Meta-analysis

TCTMD’s Top 10 Most Popular Stories for January 2025

Colchicine Surprise: No Help Post-MI, Large CLEAR SYNERGY Trial Shows

ESC’s 2024 CCS Guidelines Embrace New Data, Smooth Old Tensions

TCTMD’s Top 10 Most Popular Stories for May 2024

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Placebo-Controlled ORBITA-2 Shows PCI Eases Symptoms in Stable Angina

STEP-HFpEF: Semaglutide Cuts Weight and Symptoms, Boosts Function

Meta-analysis Finds No Excess Mortality Risk With Coronary Revascularization

CV Risk Disparities by Race/Ethnicity Persist in Childhood Cancer Survivors

AIMI-HF Misses Mark With Advanced Imaging in Ischemic HFrEF Workup

Most Patient-Reported Outcome Measures in CVD Fall Short

No Difference in 1-Year QoL Between FFR-Guided PCI and CABG: FAME-3

USPSTF at Last Takes Tougher Stance on Aspirin in Primary Prevention

No Survival Benefit With Revascularization in Stable CAD, Meta-analysis Confirms

CLARIFY at 5 Years: Angina Predictive of MI/CV Death Only in Prior MI Patients

New ‘Chronic Coronary Syndrome’ Guidelines Stress There’s Nothing Stable About CAD

Dreams Dashed: Intravascular Therapy for MS Flops in Sham-Controlled Trial

ORBITA: PCI Offers No Symptom Improvement Over Sham Procedure

Pharmacist Management of High Cholesterol Gets More Patients to Goal, Lowers LDL Levels: RxACT

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content